{"nctId":"NCT00307684","briefTitle":"Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)","startDateStruct":{"date":"2006-01"},"conditions":["Attention Deficit Disorder With Hyperactivity"],"count":155,"armGroups":[{"label":"001","type":"EXPERIMENTAL","interventionNames":["Drug: open label PR OROS methylphenidate"]},{"label":"002","type":"EXPERIMENTAL","interventionNames":["Drug: double blind PR OROS methylphenidate"]},{"label":"003","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: double blind placebo"]}],"interventions":[{"name":"double blind placebo","otherNames":[]},{"name":"double blind PR OROS methylphenidate","otherNames":[]},{"name":"open label PR OROS methylphenidate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient has completed study CR002479 (42603ATT3002), according to protocol\n* Diagnosis of ADHD according to the Diagnostic and Statistical Manual of Mental Diseases, Fourth Edition (DSM-IV)1 and confirmed by the Conners' Adult ADHD Diagnostic Interview for DSM IV (CAADID)\n* Healthy on the basis of physical examination, medical history\n* Patient is able to comply with the study visit schedule and willing and able to complete the protocol-specified assessments\n* Amendment (double-blind placebo-controlled period): written informed consent\n* patient must have completed at least 52 weeks of open-label treatment and must have been on a stable daily dose of (PR) OROS methlyphenidate prior to inclusion to this phase\n\nExclusion Criteria:\n\n* Patient is known to be a non-responder to methylphenidate, or patient has a child known to be a non-responder to methylphenidate\n* Allergy or hypersensitivty to methlyphenidate\n* Any clinically unstable psychiatric condition including but not limited to the following: acute mood disorder, bipolar disorder, acute obsessive-compulsive disorder (OCD), Anti-social personality disorder, borderline personality disorder\n* Use of other anti-depressants (unless patient has been on a stable dosage during the 42603ATT3002 trial, in which case treatment may continue as long as dosage remains unchanged for the duration of the study) or mood stabilisers (e.g. anti-epileptics, lithium)\n* Any medication likely to interfere with safe administration of methylphenidate, or any conditions that are contraindicated for use of methlyphenidate","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"To evaluate the long term safety and tolerability of PR OROS MPH (18, 36, 54, 72 and 90 mg/day) in adults with Attention Deficit Hyperactivity Disorder (ADHD)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"126","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"62","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From OL Baseline to OL Endpoint in Conners' Adult ADHD Rating Scale (CAARS) Total and Subscale Scores","description":"Long term efficacy of PR OROS MPH as assessed by investigator-rated CAARS total score, hyperactivity/impulsivity subscale score and inattention subscale score.\n\nSubscale scores: best value: 0, worst value: 27","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"-1.9","spread":"7.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"-1.0","spread":"4.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"-0.9","spread":"4.36"}]}]}]},{"type":"PRIMARY","title":"Change From DB Baseline in Conners' Adult ADHD Rating Scale (CAARS) Total Score at DB Endpoint","description":"To evaluate maintenance of treatment effects of PR OROS MPH vs. placebo as measured on CAARS.\n\nCAARS assesses ADHD symptoms and behaviors in adults. best value: 0 worst value: 54\n\nEndpoint: last available post-baseline assessment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"7.61"},{"groupId":"OG001","value":"6.5","spread":"7.82"}]}]}]},{"type":"SECONDARY","title":"Change From OL Baseline in Clinical Global Impression Scale (CGI-S) Score at OL Endpoint","description":"Assessment of the long term effect on overall functioning measured by CGI-S best score: 1 worst score: 7","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"-0.3","spread":"1.10"}]}]}]},{"type":"SECONDARY","title":"Change From OL Baseline in Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Score at OL Endpoint","description":"Quality of life measured by Q-LES-Q best score: 100 worst score: 0","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG002","value":"1.4","spread":"15.15"}]}]}]},{"type":"SECONDARY","title":"Change From DB Baseline to DB Endpoint in CGI-S Score","description":"evaluation of treatment effects as rated by the investigator on the CGI-S scale. CGI-S is used to rate the severity of a subject's illness on a 7- point scale ranging from 1 (not ill) to 7 (extremely severe).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.08"},{"groupId":"OG001","value":"1.0","spread":"1.23"}]}]}]},{"type":"SECONDARY","title":"Change From DB Baseline to DB Endpoint in CAARS Self Rated Scale (CAARS-S:S) Total Score","description":"Evaluation of treatment effects as rated by the subjects on the CAARS-S:S. best score: 0 worst score: 104","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"11.90"},{"groupId":"OG001","value":"4.0","spread":"11.98"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":23},"commonTop":["Headache","Nasopharyngitis","Restlessness","Influenza","Insomnia"]}}}